Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Humaniston Sep 04, 2020 9:39am
153 Views
Post# 31509617

IMPT DEBATE ABOUT CBD CLASSIFICATION IN GERMANY !

IMPT DEBATE ABOUT CBD CLASSIFICATION IN GERMANY !German group rejects CBD narcotic classification, wants sales only via prescription

Sep 3, 202/ 10: am

An association of pharmacies dispensing medical cannabis in Germany spurned the idea that CBD ought to be considered a narcotic but wants the cannabinoid to remain available only via prescription.

The German Association for Cannabis Dispensing Pharmacies said in a news release that “CBD is an important ingredient of the cannabis plant, which both influences the effects of THC and can trigger significant effects due to its ability to activate special receptors of the body’s endocannabinoid system.”

“As a result, CBD is classified as an active pharmaceutical ingredient and must be treated as such.”

Asked by Marijuana Business Daily to confirm whether the position stated in the German-language news release is that CBD should be sold only via doctor prescription and not over the counter, an association spokesperson replied via email that the organization “opposes the classification of CBD as a narcotic but supports at current state of research selling (it) only under prescription.”

The pharmacy association issued the communication amid an ongoing European debate about whether plant-derived CBD should be considered a narcotic.

Using Epidiolex as an example, the association said in the release that CBD has no intoxicating effect, so it should not be considered a narcotic.

However, the association is concerned about CBD being freely sold as a foodstuff.
“(CBD) deserves the chance to be perceived as an effective drug,” the association said.

Selling “non-standardized” CBD products as foodstuffs could eventually result in a “negative appraisal of the cannabinoid from authorities and health insurance companies.”
 


<< Previous
Bullboard Posts
Next >>